Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
DRUG:
Lenvima (lenvatinib)
i
Other names:
E7080, E-7080, E 7080, ER 20349200, ER-203492-00, MK-7902, ER20349200, ER-20349200, MK7902, MK 7902
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Associations
(90)
News
Trials
Company:
Eisai, Knight Therap, Merck (MSD)
Drug class:
c-KIT inhibitor, FGFR inhibitor, VEGFR inhibitor, RET inhibitor, PDGFR α antagonist
Related drugs:
‹
dasatinib (215)
imatinib (166)
sunitinib (139)
YD312 (21)
ripretinib (11)
MLN518 (8)
SU5614 (6)
pexidartinib (6)
flumatinib (5)
ABT-869 (2)
AG-1296 (1)
IDRX-42 (1)
OSI-930 (1)
MP470 (1)
PLX9486 (1)
CS 2164 (1)
E7050 (1)
CDX-0158 (0)
NB003 (0)
NMS-088 (0)
JSP191 (0)
TSU-68 (0)
BAY 57- 9352 (0)
PTK787 (0)
erdafitinib (70)
infigratinib (53)
futibatinib (52)
pemigatinib (41)
ABSK091 (32)
BAY 1163877 (23)
Debio 1347 (17)
ARQ 087 (12)
TKI258 (9)
WXSH0011 (5)
ICP-192 (5)
CPL304110 (4)
E 3810 (4)
ABSK121 (3)
KIN-3248 (3)
AZ8010 (2)
tasurgratinib (2)
MPT0L145 (1)
PRN1371 (1)
EOC317 (0)
SSR 128129 (0)
SYHA1815 (0)
XL228 (0)
BAY 1179470 (0)
TAR-210 (0)
PI-88 (0)
SYHA1817 (0)
axitinib (34)
fruquintinib (24)
cediranib (9)
surufatinib (7)
MGCD265 (4)
OMP-305B83 (3)
DC101 (1)
vorolanib (1)
KD019 (1)
BMS690514 (0)
CVX-241 (0)
ESK981 (0)
adAptVEGF-C adenoviral vector (0)
SU 14813 (0)
SYHA1813 (0)
VEGFR1-1084 (0)
ABT-165 (0)
IMC-18F1 (0)
ABT348 (0)
SU5416 (0)
GS 6624 (0)
RG7221 (0)
selpercatinib (67)
pralsetinib (49)
TAS0953/HM06 (7)
AST-487 (5)
RXDX-105 (5)
EP0031 (4)
FHND5071 (4)
BOS-172738 (3)
HG-6-63-01 (2)
SY-5007 (2)
TY-1091 (2)
XMD15-44 (2)
TPX-0046 (2)
HSL468 (1)
HSL476 (1)
HSN608 (1)
LDD-2633 (1)
PLD-102 (1)
APS03118 (0)
BTG-002814 (0)
HS-10365 (0)
HS269 (0)
JNJ-26483327 (0)
LOXO-260 (0)
PLD-101 (0)
SKI-G-801 (0)
olaratumab (1)
dasatinib (215)
imatinib (166)
sunitinib (139)
YD312 (21)
ripretinib (11)
MLN518 (8)
SU5614 (6)
pexidartinib (6)
flumatinib (5)
ABT-869 (2)
AG-1296 (1)
IDRX-42 (1)
OSI-930 (1)
MP470 (1)
PLX9486 (1)
CS 2164 (1)
E7050 (1)
CDX-0158 (0)
NB003 (0)
NMS-088 (0)
JSP191 (0)
TSU-68 (0)
BAY 57- 9352 (0)
PTK787 (0)
erdafitinib (70)
infigratinib (53)
futibatinib (52)
pemigatinib (41)
ABSK091 (32)
BAY 1163877 (23)
Debio 1347 (17)
ARQ 087 (12)
TKI258 (9)
WXSH0011 (5)
ICP-192 (5)
CPL304110 (4)
E 3810 (4)
ABSK121 (3)
KIN-3248 (3)
AZ8010 (2)
tasurgratinib (2)
MPT0L145 (1)
PRN1371 (1)
EOC317 (0)
SSR 128129 (0)
SYHA1815 (0)
XL228 (0)
BAY 1179470 (0)
TAR-210 (0)
PI-88 (0)
SYHA1817 (0)
axitinib (34)
fruquintinib (24)
cediranib (9)
surufatinib (7)
MGCD265 (4)
OMP-305B83 (3)
DC101 (1)
vorolanib (1)
KD019 (1)
BMS690514 (0)
CVX-241 (0)
ESK981 (0)
adAptVEGF-C adenoviral vector (0)
SU 14813 (0)
SYHA1813 (0)
VEGFR1-1084 (0)
ABT-165 (0)
IMC-18F1 (0)
ABT348 (0)
SU5416 (0)
GS 6624 (0)
RG7221 (0)
selpercatinib (67)
pralsetinib (49)
TAS0953/HM06 (7)
AST-487 (5)
RXDX-105 (5)
EP0031 (4)
FHND5071 (4)
BOS-172738 (3)
HG-6-63-01 (2)
SY-5007 (2)
TY-1091 (2)
XMD15-44 (2)
TPX-0046 (2)
HSL468 (1)
HSL476 (1)
HSN608 (1)
LDD-2633 (1)
PLD-102 (1)
APS03118 (0)
BTG-002814 (0)
HS-10365 (0)
HS269 (0)
JNJ-26483327 (0)
LOXO-260 (0)
PLD-101 (0)
SKI-G-801 (0)
olaratumab (1)
›
Associations
(90)
News
Trials
VERI cancer hierarchy
Reset Filters
No biomarker
Thymic Carcinoma
No biomarker
Thymic Carcinoma
lenvatinib
Sensitive: A1 - Approval
lenvatinib
Sensitive
:
A1
lenvatinib
Sensitive: A1 - Approval
lenvatinib
Sensitive
:
A1
No biomarker
Thyroid Gland Follicular Carcinoma
No biomarker
Thyroid Gland Follicular Carcinoma
lenvatinib
Sensitive: A1 - Approval
lenvatinib
Sensitive
:
A1
lenvatinib
Sensitive: A1 - Approval
lenvatinib
Sensitive
:
A1
No biomarker
Thyroid Gland Hurthle Cell Carcinoma
No biomarker
Thyroid Gland Hurthle Cell Carcinoma
lenvatinib
Sensitive: A1 - Approval
lenvatinib
Sensitive
:
A1
lenvatinib
Sensitive: A1 - Approval
lenvatinib
Sensitive
:
A1
No biomarker
Thyroid Gland Papillary Carcinoma
No biomarker
Thyroid Gland Papillary Carcinoma
lenvatinib
Sensitive: A1 - Approval
lenvatinib
Sensitive
:
A1
lenvatinib
Sensitive: A1 - Approval
lenvatinib
Sensitive
:
A1
No biomarker
Endometrial Cancer
No biomarker
Endometrial Cancer
pembrolizumab + lenvatinib
Sensitive: A1 - Approval
pembrolizumab + lenvatinib
Sensitive
:
A1
pembrolizumab + lenvatinib
Sensitive: A1 - Approval
pembrolizumab + lenvatinib
Sensitive
:
A1
No biomarker
Renal Cell Carcinoma
No biomarker
Renal Cell Carcinoma
everolimus + lenvatinib
Sensitive: A1 - Approval
everolimus + lenvatinib
Sensitive
:
A1
everolimus + lenvatinib
Sensitive: A1 - Approval
everolimus + lenvatinib
Sensitive
:
A1
No biomarker
Thyroid Gland Carcinoma
No biomarker
Thyroid Gland Carcinoma
lenvatinib
Sensitive: A1 - Approval
lenvatinib
Sensitive
:
A1
lenvatinib
Sensitive: A1 - Approval
lenvatinib
Sensitive
:
A1
No biomarker
Hepatocellular Cancer
No biomarker
Hepatocellular Cancer
lenvatinib
Sensitive: A1 - Approval
lenvatinib
Sensitive
:
A1
lenvatinib
Sensitive: A1 - Approval
lenvatinib
Sensitive
:
A1
No biomarker
Renal Cell Carcinoma
No biomarker
Renal Cell Carcinoma
pembrolizumab + lenvatinib
Sensitive: A1 - Approval
pembrolizumab + lenvatinib
Sensitive
:
A1
pembrolizumab + lenvatinib
Sensitive: A1 - Approval
pembrolizumab + lenvatinib
Sensitive
:
A1
MSI-H/dMMR
Endometrial Cancer
MSI-H/dMMR
Endometrial Cancer
pembrolizumab + lenvatinib
Sensitive: A2 - Guideline
pembrolizumab + lenvatinib
Sensitive
:
A2
pembrolizumab + lenvatinib
Sensitive: A2 - Guideline
pembrolizumab + lenvatinib
Sensitive
:
A2
No biomarker
Clear Cell Renal Cell Carcinoma
No biomarker
Clear Cell Renal Cell Carcinoma
lenvatinib
Sensitive: A2 - Guideline
lenvatinib
Sensitive
:
A2
lenvatinib
Sensitive: A2 - Guideline
lenvatinib
Sensitive
:
A2
No biomarker
Biliary Tract Cancer
No biomarker
Biliary Tract Cancer
pembrolizumab + lenvatinib
Sensitive: A2 - Guideline
pembrolizumab + lenvatinib
Sensitive
:
A2
pembrolizumab + lenvatinib
Sensitive: A2 - Guideline
pembrolizumab + lenvatinib
Sensitive
:
A2
No biomarker
Clear Cell Renal Cell Carcinoma
No biomarker
Clear Cell Renal Cell Carcinoma
pembrolizumab + lenvatinib
Sensitive: A2 - Guideline
pembrolizumab + lenvatinib
Sensitive
:
A2
pembrolizumab + lenvatinib
Sensitive: A2 - Guideline
pembrolizumab + lenvatinib
Sensitive
:
A2
No biomarker
Cutaneous Melanoma
No biomarker
Cutaneous Melanoma
pembrolizumab + lenvatinib
Sensitive: A2 - Guideline
pembrolizumab + lenvatinib
Sensitive
:
A2
pembrolizumab + lenvatinib
Sensitive: A2 - Guideline
pembrolizumab + lenvatinib
Sensitive
:
A2
No biomarker
Kidney Cancer
No biomarker
Kidney Cancer
everolimus + lenvatinib
Sensitive: A2 - Guideline
everolimus + lenvatinib
Sensitive
:
A2
everolimus + lenvatinib
Sensitive: A2 - Guideline
everolimus + lenvatinib
Sensitive
:
A2
No biomarker
Kidney Cancer
No biomarker
Kidney Cancer
pembrolizumab + lenvatinib
Sensitive: A2 - Guideline
pembrolizumab + lenvatinib
Sensitive
:
A2
pembrolizumab + lenvatinib
Sensitive: A2 - Guideline
pembrolizumab + lenvatinib
Sensitive
:
A2
RET fusion
Lung Cancer
RET fusion
Lung Cancer
lenvatinib
Sensitive: B - Late Trials
lenvatinib
Sensitive
:
B
lenvatinib
Sensitive: B - Late Trials
lenvatinib
Sensitive
:
B
FGF21 elevation
Hepatocellular Cancer
FGF21 elevation
Hepatocellular Cancer
lenvatinib
Sensitive: B - Late Trials
lenvatinib
Sensitive
:
B
lenvatinib
Sensitive: B - Late Trials
lenvatinib
Sensitive
:
B
VEGFA elevation
Hepatocellular Cancer
VEGFA elevation
Hepatocellular Cancer
lenvatinib
Resistant: B - Late Trials
lenvatinib
Resistant
:
B
lenvatinib
Resistant: B - Late Trials
lenvatinib
Resistant
:
B
PD-L1 expression
Non Small Cell Lung Cancer
PD-L1 expression
Non Small Cell Lung Cancer
pembrolizumab + lenvatinib
Sensitive: B - Late Trials
pembrolizumab + lenvatinib
Sensitive
:
B
pembrolizumab + lenvatinib
Sensitive: B - Late Trials
pembrolizumab + lenvatinib
Sensitive
:
B
No biomarker
Hepatocellular Cancer
No biomarker
Hepatocellular Cancer
pembrolizumab + lenvatinib
Sensitive: B - Late Trials
pembrolizumab + lenvatinib
Sensitive
:
B
pembrolizumab + lenvatinib
Sensitive: B - Late Trials
pembrolizumab + lenvatinib
Sensitive
:
B
PD-L1 expression
Gastric Cancer
PD-L1 expression
Gastric Cancer
pembrolizumab + lenvatinib
Sensitive: C2 – Inclusion Criteria
pembrolizumab + lenvatinib
Sensitive
:
C2
pembrolizumab + lenvatinib
Sensitive: C2 – Inclusion Criteria
pembrolizumab + lenvatinib
Sensitive
:
C2
PD-L1 expression
Biliary Tract Cancer
PD-L1 expression
Biliary Tract Cancer
pembrolizumab + lenvatinib
Sensitive: C2 – Inclusion Criteria
pembrolizumab + lenvatinib
Sensitive
:
C2
pembrolizumab + lenvatinib
Sensitive: C2 – Inclusion Criteria
pembrolizumab + lenvatinib
Sensitive
:
C2
ER positive
HER2 Negative Breast Cancer
ER positive
HER2 Negative Breast Cancer
lenvatinib
Sensitive: C2 – Inclusion Criteria
lenvatinib
Sensitive
:
C2
lenvatinib
Sensitive: C2 – Inclusion Criteria
lenvatinib
Sensitive
:
C2
DDR
Cholangiocarcinoma
DDR
Cholangiocarcinoma
lenvatinib + toripalimab-tpzi
Sensitive: C3 – Early Trials
lenvatinib + toripalimab-tpzi
Sensitive
:
C3
lenvatinib + toripalimab-tpzi
Sensitive: C3 – Early Trials
lenvatinib + toripalimab-tpzi
Sensitive
:
C3
PD-L1 expression
Cholangiocarcinoma
PD-L1 expression
Cholangiocarcinoma
lenvatinib + toripalimab-tpzi
Sensitive: C3 – Early Trials
lenvatinib + toripalimab-tpzi
Sensitive
:
C3
lenvatinib + toripalimab-tpzi
Sensitive: C3 – Early Trials
lenvatinib + toripalimab-tpzi
Sensitive
:
C3
KIF5B-RET fusion
Non Small Cell Lung Cancer
KIF5B-RET fusion
Non Small Cell Lung Cancer
lenvatinib
Sensitive: C3 – Early Trials
lenvatinib
Sensitive
:
C3
lenvatinib
Sensitive: C3 – Early Trials
lenvatinib
Sensitive
:
C3
PIK3R1 mutation
Hormone Receptor Positive Breast Cancer
PIK3R1 mutation
Hormone Receptor Positive Breast Cancer
lenvatinib
Resistant: C3 – Early Trials
lenvatinib
Resistant
:
C3
lenvatinib
Resistant: C3 – Early Trials
lenvatinib
Resistant
:
C3
USH2A mutation
Hormone Receptor Positive Breast Cancer
USH2A mutation
Hormone Receptor Positive Breast Cancer
lenvatinib
Sensitive: C3 – Early Trials
lenvatinib
Sensitive
:
C3
lenvatinib
Sensitive: C3 – Early Trials
lenvatinib
Sensitive
:
C3
NEFH mutation
Hormone Receptor Positive Breast Cancer
NEFH mutation
Hormone Receptor Positive Breast Cancer
lenvatinib
Sensitive: C3 – Early Trials
lenvatinib
Sensitive
:
C3
lenvatinib
Sensitive: C3 – Early Trials
lenvatinib
Sensitive
:
C3
APC mutation
Hormone Receptor Positive Breast Cancer
APC mutation
Hormone Receptor Positive Breast Cancer
lenvatinib
Resistant: C3 – Early Trials
lenvatinib
Resistant
:
C3
lenvatinib
Resistant: C3 – Early Trials
lenvatinib
Resistant
:
C3
PTCH1 mutation
Hormone Receptor Positive Breast Cancer
PTCH1 mutation
Hormone Receptor Positive Breast Cancer
lenvatinib
Sensitive: C3 – Early Trials
lenvatinib
Sensitive
:
C3
lenvatinib
Sensitive: C3 – Early Trials
lenvatinib
Sensitive
:
C3
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login